Pharmacogenomics of Sulfonylureas Response in Relation to rs7754840 Polymorphisms in Cyclin-Dependent Kinase 5 Regulatory Subunit-associated Protein 1-like (CDKAL1) Gene in Iranian Type 2 Diabetes Patients

Soltani, Goljahan; Hatefi, Zahra; Salehi, Ahmad Reza; Khosravi, Sharifeh; Ghiasi, Moosa Rahimi; Teke, Keimer; Aminorroaya, Ashraf; Salehi, Rasoul

Pharmacogenomics of Sulfonylureas Response in Relation to rs7754840 Polymorphisms in Cyclin-Dependent Kinase 5 Regulatory Subunit-associated Protein 1-like (CDKAL1) Gene in Iranian Type 2 Diabetes Patients

Document Type : Original Article

Authors

¹ Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Tehran, Iran

² Iranian Blood Transfusion Organization Research Centre, Tehran, Iran

³ Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Sulfonylureas are important drugs of choice for treatment of type 2 diabetes mellitus (T2DM). It is suggested that differential response to sulfonylureas from T2DM patients is under influence of single nucleotide polymorphisms in some of the target genes. In spite of favorable therapeutic effects, sulfonylureas are associated with some adverse side effects such as microvascular complications and stroke, especially in older patients. Therefore, for T2DM patients who are getting less benefit, sulfonylureas should be avoided. Cyclin-dependent kinase 5 regulatory subunit-associated protein 1-like (CDKAL1) gene variation is reported to be associated with sulfonylureas effectiveness. Due to the inconsistency of available data regarding association of rs7754840 in CDKAL1 gene with sulfonylureas response in T2DM patients, the present study is conducted. Materials and Methods: Fifty-one diabetic patients sensitive to sulfonylureas and 51 patients resistant to sulfonylureas treatment were recruited to this study. After extraction of DNA from patients' peripheral blood samples, rs7754840 single-nucleotide polymorphism was genotyped by polymerase chain reaction-restriction fragment length polymorphism assay using MaeII (Tail) restriction enzyme. Results: Frequency of G allele in resistant group was more than sensitive group (71, 6% vs. 57, 8%). Regression analysis was shown significant association between GG genotype and higher risk of resistance to sulfonylureas treatment (odds ratio = 2.250 [95% confidential intervals: 1.010–5.012]; P = 0.046). Conclusion: Our data confirmed that genotypes of rs7754840 are significantly associated with sulfonylureas treatment response. rs7754840 in CDKAL1 gene in combination with other clinicopathological findings would help to move towards personalized therapy of T2DM patients.

Keywords

References

1.	Kong AP, Luk AO, Chan JC. Detecting people at high risk of type 2 diabetes- how do we find them and who should be treated? Best Pract Res Clin Endocrinol Metab 2016;30:345-55. [PUBMED]
2.	Bain SC, Feher M, Russell-Jones D, Khunti K. Management of type 2 diabetes: The current situation and key opportunities to improve care in the UK. Diabetes Obes Metab 2016;18:1157-66.
3.	Yang Y, Wang Y, Zhou K, Hong A. Constructing regulatory networks to identify biomarkers for insulin resistance. Gene 2014;539:68-74. [PUBMED]
4.	Wheeler E, Barroso I. Genome-wide association studies and type 2 diabetes. Brief Funct Genomics 2011;10:52-60. [PUBMED]
5.	Ashcroft FM, Rorsman P. Diabetes mellitus and the β cell: The last ten years. Cell 2012;148:1160-71. [PUBMED]
6.	Cefalu WT. Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: Rationale and specific agents. Clin Pharmacol Ther 2007;81:636-49. [PUBMED]
7.	El-Sisi AE, Hegazy SK, Metwally SS, Wafa AM, Dawood NA. Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in Egyptian patients with type 2 diabetes. Ther Adv Endocrinol Metab 2011;2:155-64. [PUBMED]
8.	McTaggart JS, Clark RH, Ashcroft FM. The role of the KATP channel in glucose homeostasis in health and disease: More than meets the islet. J Physiol 2010;588:3201-9. [PUBMED]
9.	Holden SE, Currie CJ. Mortality risk with sulphonylureas compared to metformin. Diabetes Obes Metab 2014;16:885-90. [PUBMED]
10.	Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN. Sulphonylureas and risk of cardiovascular disease: Systematic review and meta-analysis. Diabet Med 2013;30:1160-71. [PUBMED]
11.	Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:938-53. [PUBMED]
12.	Miller M, Knatterud G, Hawkins BS. A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976;25:1129-53.
13.	Schroner Z, Javorský M, Halušková J, Klimčáková L, Babjaková E, Fabianová M, et al. Variation in CDKAL1 gene is associated with therapeutic response to sulphonylureas. Physiol Res 2012;61:177-83.
14.	Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316:1331-6. [PUBMED]
15.	Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. Agenome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341-5. [PUBMED]
16.	Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, et al. Avariant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007;39:770-5. [PUBMED]
17.	Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007;316:1336-41. [PUBMED]
18.	Takeuchi F, Serizawa M, Yamamoto K, Fujisawa T, Nakashima E, Ohnaka K, et al. Confirmation of multiple risk Loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population. Diabetes 2009;58:1690-9. [PUBMED]
19.	Ohara-Imaizumi M, Yoshida M, Aoyagi K, Saito T, Okamura T, Takenaka H, et al. Deletion of CDKAL1 affects mitochondrial ATP generation and first-phase insulin exocytosis. PLoS One 2010;5:e15553. [PUBMED]
20.	Dehwah MA, Wang M, Huang QY. CDKAL1 and type 2 diabetes: A global meta-analysis. Genet Mol Res 2010;9:1109-20. [PUBMED]
21.	Ubeda M, Rukstalis JM, Habener JF. Inhibition of cyclin-dependent kinase 5 activity protects pancreatic beta cells from glucotoxicity. J Biol Chem 2006;281:28858-64. [PUBMED]
22.	Lew J, Huang QQ, Qi Z, Winkfein RJ, Aebersold R, Hunt T, et al. Abrain-specific activator of cyclin-dependent kinase 5. Nature 1994;371:423-6. [PUBMED]
23.	Sim X, Ong RT, Suo C, Tay WT, Liu J, Ng DP, et al. Transferability of type 2 diabetes implicated loci in multi-ethnic cohorts from Southeast Asia. PLoS Genet 2011;7:e1001363. [PUBMED]
24.	Tuerxunyiming M, Mohemaiti P, Wufuer H, Tuheti A. Association of rs7754840 G/C polymorphisms in CDKAL1 with type 2 diabetes: A meta-analysis of 70141 subjects. Int J Clin Exp Med 2015;8:17392-405. [PUBMED]
25.	Groenewoud MJ, Dekker JM, Fritsche A, Reiling E, Nijpels G, Heine RJ, et al. Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia 2008;51:1659-63. [PUBMED]
26.	Stancáková A, Pihlajamäki J, Kuusisto J, Stefan N, Fritsche A, Häring H, et al. Single-nucleotide polymorphism rs7754840 of CDKAL1 is associated with impaired insulin secretion in nondiabetic offspring of type 2 diabetic subjects and in a large sample of men with normal glucose tolerance. J Clin Endocrinol Metab 2008;93:1924-30.
27.	Kirchhoff K, Machicao F, Haupt A, Schäfer SA, Tschritter O, Staiger H, et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 2008;51:597-601.
28.	Palmer ND, Goodarzi MO, Langefeld CD, Ziegler J, Norris JM, Haffner SM, et al. Quantitative trait analysis of type 2 diabetes susceptibility loci identified from whole genome association studies in the Insulin Resistance Atherosclerosis Family Study. Diabetes 2008;57:1093-100. [PUBMED]
29.	Mansoori Y, Daraei A, Naghizadeh MM, Salehi R. Significance of a common variant in the CDKAL1 gene with susceptibility to type 2 diabetes mellitus in Iranian population. Adv Biomed Res 2015;4:45. [PUBMED] [Full text]
30.	Chistiakov DA, Potapov VA, Smetanina SA, Bel'chikova LN, Suplotova LA, Nosikov VV, et al. The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel. Acta Diabetol 2011;48:227-35.
31.	Ren Q, Han X, Tang Y, Zhang X, Zou X, Cai X, et al. Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. Diabetologia 2014;57:746-53. [PUBMED]
32.	Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet 1998;352:837-53. [PUBMED]
33.	Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
34.	Reitman ML, Schadt EE. Pharmacogenetics of metformin response: A step in the path toward personalized medicine. J Clin Invest 2007;117:1226-9. [PUBMED]
35.	Loganadan NK, Huri HZ, Vethakkan SR, Hussein Z. Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: Current evidence and challenges for clinical implementation. Pharmacogenomics J 2016;16:209-19.
36.	Sehra D, Sehra S, Sehra ST. Sulfonylureas: Do we need to introspect safety again? Expert Opin Drug Saf 2011;10:851-61. [PUBMED]
37.	Nordin C. The case for hypoglycaemia as a proarrhythmic event: Basic and clinical evidence. Diabetologia 2010;53:1552-61. [PUBMED]
38.	Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2003;111:405-14. [PUBMED]
39.	Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-8. [PUBMED]
40.	Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000;49:1751-60. [PUBMED]
41.	Shimajiri Y, Yamana A, Morita S, Furuta H, Furuta M, Sanke T, et al. Kir6.2 E23K polymorphism is related to secondary failure of sulfonylureas in non-obese patients with type 2 diabetes. J Diabetes Investig 2013;4:445-9.
42.	Osada UN, Sunagawa H, Terauchi Y, Ueda S. A common susceptibility gene for type 2 diabetes is associated with drug response to a DPP-4 inhibitor: Pharmacogenomic cohort in Okinawa Japan. PLoS One 2016;11:e0154821.

Advanced Biomedical Research